Trials / Completed
CompletedNCT00742508
A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure
A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Failure (Phase I/II Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SK&F-105517-D 10 mg capsule | 1 capsule once a day |
| DRUG | Carvedilol-immediate release (IR) 2.5 mg tablet | 1 or 2 tablet(s) twice a day |
| DRUG | SK&F-105517-D 20 mg capsule | 1 capsule once a day |
| DRUG | SK&F-105517-D 40 mg capsule | 1 or 2 capsule(s) once a day |
| DRUG | Carvedilol-IR 10 mg tablet | 1 tablet twice a day |
Timeline
- Start date
- 2008-08-28
- Primary completion
- 2009-08-21
- Completion
- 2009-08-21
- First posted
- 2008-08-27
- Last updated
- 2017-08-02
- Results posted
- 2010-08-19
Locations
23 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00742508. Inclusion in this directory is not an endorsement.